Edwards Lifesciences (EW) put fresh clinical data for its EVOQUE tricuspid valve system in the spotlight at the ACC.26 conference, highlighting sustained patient benefits and lower mortality in the TRISCEND II trial.
See our latest analysis for Edwards Lifesciences.
At a share price of $81.19, Edwards Lifesciences has seen a 17.67% 1 year total shareholder return. The 90 day share price return of a 5.43% decline suggests recent momentum has cooled despite supportive EVOQUE trial headlines.
If the EVOQUE data has you thinking about where medical technology could head next, it may be worth scanning other potential healthcare leaders with 37 healthcare AI stocks
With Edwards Lifesciences trading at $81.19, showing a 17.67% 1-year total return and an 8.65% intrinsic discount, a key question arises for investors: is this a genuine entry point, or has the market already priced in future growth?
Most Popular Narrative: 16.4% Undervalued
With Edwards Lifesciences last closing at $81.19 against a narrative fair value of $97.12, the current setup centers on whether the market is underestimating its future earnings power based on detailed long term forecasts.
The analysts have a consensus price target of $97.12 for Edwards Lifesciences based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $110.0, and the most bearish reporting a price target of just $84.0.
Read the complete narrative. Read the complete narrative.
Analysts are incorporating assumptions for faster earnings growth, higher profit margins, and a premium P/E several years out. Want to see exactly which assumptions justify that higher fair value and how they compare to today’s share price trajectory?
Result: Fair Value of $97.12 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the story can change quickly if tariffs bite harder than expected or if competitive pressure in markets like Japan weighs on TAVR procedure volumes.
Find out about the key risks to this Edwards Lifesciences narrative.
Another View: High P/E Points To Rich Expectations
While the narrative fair value of $97.12 suggests Edwards Lifesciences is 16.4% undervalued, the current P/E of 44.2x tells a different story. It sits well above the US Medical Equipment industry at 26.6x, peers at 26.5x, and even the fair ratio of 32.8x, which hints at valuation risk if growth or margins fall short.
For a closer look at how this price compares to earnings power across peers and that fair ratio the market could move toward, See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
If this mix of optimism and concern feels familiar, it is because the story has both. Move quickly, review the data, and weigh the 2 key rewards and 3 important warning signs.
Ready to find your next idea?
If Edwards Lifesciences has sharpened your focus on quality, do not stop here. Use the screeners below to quickly surface other stocks that fit clear, disciplined criteria.
- Target resilient balance sheets and steady fundamentals with the solid balance sheet and fundamentals stocks screener (40 results).
- Spot potential value opportunities before they hit the spotlight by running the screener containing 25 high quality undiscovered gems.
- Zero in on companies that combine quality with pricing that still looks attractive using the 62 high quality undervalued stocks.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com